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Abstract
During the past decade, genomic microarrays have been applied with some success to the
molecular profiling of breast tumours, which has resulted in a much more detailed classification
scheme as well as in the identification of potential gene signature sets. These gene sets have been
applied to both the prognosis and prediction of outcome to treatment and have performed better
than the current clinical criteria. One of the main limitations of microarray analysis, however, is
that frozen tumour samples are required for the assay. This imposes severe limitations on access
to samples and precludes large scale validation studies from being conducted. Quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR), on the other hand, can be used with degraded
RNAs derived from formalin-fixed paraffin-embedded (FFPE) tumour samples, the most important
and abundant source of clinical material available. More recently, the novel DASL (cDNA-mediated
Annealing, Selection, extension and Ligation) assay has been developed as a high throughput gene
expression profiling system specifically designed for use with FFPE tumour tissue samples.
However, we do not believe that genomics is adequate as a sole prognostic and predictive platform
in breast cancer. The key proteins driving oncogenesis, for example, can undergo post-translational
modifications; moreover, if we are ever to move individualization of therapy into the practical
world of blood-based assays, serum proteomics becomes critical. Proteomic platforms, including
tissue micro-arrays (TMA) and protein chip arrays, in conjunction with surface-enhanced laser
desorption ionization time-of-flight mass spectrometry (SELDI-TOF/MS), have been the
technologies most widely applied to the characterization of tumours and serum from breast cancer
patients, with still limited but encouraging results.
This review will focus on these genomic and proteomic platforms, with an emphasis placed on the
utilization of FFPE tumour tissue samples and serum, as they have been applied to the study of
breast cancer for the discovery of gene signatures and biomarkers for the early diagnosis, prognosis
and prediction of treatment outcome. The ultimate goal is to be able to apply a systems biology
approach to the information gleaned from the combination of these techniques in order to select
the best treatment strategy, monitor its effectiveness and make changes as rapidly as possible
where needed to achieve the optimal therapeutic results for the patient.
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Background
In the United States it is estimated that approximately
213,000 new cases of invasive breast cancer will be diag-
nosed in 2006 and 41,000 women are expected to die
from this disease [1]. Breast cancer will account for ~31%
of new cancer cases among women in the United states in
2006 [1]. Current treatment strategies rely mainly on ana-
tomic staging that continues to play a significant role in
the decision making process. Classical pathological
indexes that are used to predict survival, development of
metastatic disease or guide selection of primary therapy in
patients with breast cancer include the Nottingham Prog-
nostic Index [2], introduced back in 1982, Adjuvant!
Online (AO) [3], and the St. Gallen criteria [4]. The Not-
tingham Prognostic Index is based upon tumour size,
lymph node stage and histological grade to predict sur-
vival in patients. AO is a program that is available through
the web that is used to assess risk for the development of
metastatic disease using traditional prognostic factors that
include age, lymph node (LN) status, tumour size,
tumour grade, and hormone receptor status. The current
St. Gallen derived algorithm for selection of adjuvant sys-
temic therapy for early breast cancer patients includes
tumour size and grade, nodal status, menopausal status,
peritumoural vessel invasion, endocrine status and HER2
(epidermal growth factor receptor 2) status. The use of
these aforementioned mainly pathology-based prognostic
tools in the treatment decision-making process are inade-
quate and, at minimum, a more precise stratification of
patients into responders versus non-responders to thera-
peutic agents is needed.
Although large clinical trials have confirmed the value of
systemic therapy, it is not possible to identify at the outset
those patients who are likely to respond to adjuvant treat-
ment or which types of treatment should be used. For
example, adjuvant therapy significantly improves survival
in breast cancer patients with both LN-negative and LN-
positive disease. It is generally accepted that breast cancer
patients with a poor prognosis would gain the most ben-
efit from adjuvant therapy (e.g. those with invasion into
axillary LNs). However, results of several studies show
that 22 to 33% of breast cancer patients with no detecta-
ble LN involvement and classified into a good prognosis
subgroup develop recurrence of disease after a 10-year fol-
low-up. Therefore, accurate identification and classifica-
tion of breast cancer patients over and above current
prognostic and predictive markers is critically important
for rational treatment decision-making and improved
clinical outcome in the individual patient, a long time
goal, albeit an elusive one, of breast cancer researchers.
Multiple chemotherapeutic agents that include anthracy-
clines, antimetabolites, microtubule inhibitors, and
alkylating agents have been used successfully in the treat-
ment of breast cancer. Although, response rates of >30%
are routinely achieved in previously untreated patients it
is still not possible to know which of these cytotoxic ther-
apies will be the most effective treatment for a particular
patient's tumour. Once treatment begins, a patient is
monitored for response and toxicity and any change in
therapy is solely based upon tumour progression or intol-
erable toxicity. Even in the case of targeted therapies in
breast cancer that hit the estrogen receptor (ER), HER2 or
EGFR (human epidermal growth factor receptor 1), the
ability to effectively monitor response is critical. Thus,
despite the development of numerous general and tar-
geted anti-cancer agents over the past two decades, more
progress is needed with regard to increasing life expect-
ancy once a woman is diagnosed with breast cancer [5].
Thus, the ability to diagnose breast cancer early, deter-
mine each woman's prognosis, predict the best treatment
modality and effectively and non-invasively monitor the
patient's progress to treatment is paramount if we are to
move forward in our fight against breast cancer.
The way forward will require a systematic approach that
will entail both genomics and proteomics if we are to
meet the goal of therapeutic individualization. The rea-
sons for this are several: 1) Molecular profiling by micro-
array, qRT-PCR or FISH- (fluorescent-in situ
hybridization) based analyses of tumours is required for
classification of tumour types that correlates with progno-
sis; 2) Analysis at the gene level, however, can not detect
the biologic subtleties introduced through posttransla-
tional modifications, glycosylations, etc. of proteins and
thus requires a proteomic approach; 3) Analysis of serum
samples for predictive markers can only be accomplished
through proteomics; and 4) Older technologies (e.g., his-
topathology and immunohistochemistry) may still prove
valuable for particular treatments in individual patients.
For instance, a genomic lead suggesting amplification of a
particular gene could be validated at the proteomic level
or through immunohistochemistry. The path to individu-
alization of therapy is complex and in the long run will
require some combination of genomic and proteomic
analysis in conjunction with existing histopathologic and
immunohistochemical analysis in order to provide a com-
plete picture of a patient's breast cancer. Only by analyz-
ing data across technology platforms and using improving
computational systems biology approaches will we be
able to eventually define all of the pieces to the puzzle.
Microarray technology has allowed for unprecedented
expression profiling of thousands of genes simultane-
ously and for the development of gene signatures to sub-
divide and categorize tumours [6] as well as predict
response to treatment [7]. However, this platform relies
on frozen tumour tissue samples which are not a readily
available source; but other complementary platforms,Proteome Science 2006, 4:5 http://www.proteomesci.com/content/4/1/5
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such as TMA, qRT-PCR and the recently described DASL
assay [8], will allow the researcher to tap into the large
resource of well annotated FFPE tumour tissue sample
repositories. Analysis of mRNA expression using any one
of these above mentioned platforms, however, provides
only a limited look at what is going on in a tumour since
repeat biopsies are not a realistic option and, therefore,
will not provide a means of following a patient's response
to therapy. This will require the ability to analyze proteins
in readily accessible serum samples from patients being
treated with various drugs using recently developed pro-
tein-chip arrays in conjunction with SELDI-TOF/MS. The
ability to monitor and predict a patient's response to ther-
apy will allow any necessary changes to therapy be made
as rapidly as possible. A systematic approach, therefore,
will entail a precise pathological and molecular classifica-
tion of the patient's tumour that would be used to select
the best possible treatment strategy, monitor the effects of
treatment in order to modify treatment as needed, and
predict recurrence of disease.
This review will focus on this systematic approach and the
application of existing and newer genomic and proteomic
technologies, introduced above, as they apply to the study
of breast cancer; approaches that will contribute to, and
change the way in which we diagnose, treat, and monitor
treatment effectiveness in patients.
Classification of breast tumours using 
microarrays
Microarray-based gene expression profiling of human
cancers has rapidly emerged as a new powerful screening
technique. Recently, breast cancer gene expression signa-
tures have been identified that are associated with ER and
LN status of patients and can aid in classifying breast can-
cer patients into subgroups with different clinical out-
comes. Moreover, gene expression signatures have been
shown to predict response to particular chemotherapy
regimens (see below). The advantage of the microarray
technology is the ability to measure the RNA expression of
thousands of genes at one time, and to relate how the
expression pattern of one gene correlates to the expression
of other genes in or between different tumour samples.
One of the first comprehensive attempts to characterize
the variation in gene expression between sporadic breast
tumour samples was published by Perou and co-workers
[9]. This groundbreaking study was the first to establish
that tumours could be phenotypically classified into sub-
types distinguishable by differences in their expression
profiles. An "intrinsic gene set" of 476 cDNAs was then
used to cluster and segregate the tumours into four major
subgroups: 1) a "luminal cell-like" group expressing ER;
2) a "basal cell-like" group expressing cytokeratins 5 and
17, integrin 4, and laminin, but lacking ER expression; 3)
a HER2-positive subset; and 4) a "normal" epithelial
group. Hence, this seminal paper identified specific sub-
types of breast tumours based upon hormone receptor
and HER2 status.
A subsequent study by the same group has extended the
molecular profiling of breast cancer by applying their
intrinsic gene set to cluster 78 cancers (the tumours from
their previous study were included in these), 3 fibroade-
nomas, and 4 normal breast tissue samples [6]. In this
study, they identified 456 genes (out of 8,102 candidate
genes) that could classify breast tumours into six subtypes
(including ER-positive, luminal subtype A; ER-positive,
luminal subtype B; ER-positive, luminal subtype C; HER2-
positive, ER-negative subtype; basal-like, ER-negative,
progesterone receptor- (PGR) negative, HER2-negative;
normal breast-like) and subsequently validated these sub-
types in an independent cohort of 49 patients with locally
advanced breast cancer. The authors found that these sub-
types were highly significantly correlated with overall sur-
vival (OS) (or the percentage of subjects in a study who
have survived for a defined period of time, usually from
the time of diagnosis). A similar classification scheme was
obtained for 99 LN-negative and LN-positive breast cancer
patients [10]. ER status was the most important discrimi-
nator of subtypes with tumour grade being a distant sec-
ond. In addition, subtypes did not strongly reflect other
clinical features, such as LN status, tumour size or meno-
pausal status, underscoring the importance of molecular
characterization of tumours.
Van't Veer and colleagues [11] have used DNA microanal-
ysis on primary breast tumours of 98 young patients and
applied supervised classification to identify a 70-gene-
expression signature strongly predictive of a short interval
to distant metastasis in LN-negative patients <55 years of
age. The poor prognostic signature consisted of genes reg-
ulating cell cycle, invasion, metastasis, and angiogenesis.
Van de Vijver and co-workers [12] subsequently used this
70-gene prognostic profile to classify a series of 295 con-
secutive patients with primary breast carcinomas as hav-
ing a gene-expression signature associated with either a
poor or a good prognosis. All patients had stage I or II
breast cancer and were younger than 53 years of age; 151
had LN-negative disease, and 144 had LN-positive dis-
ease. The predictive power of the prognostic profile was
validated using univariate and multivariate statistical
analyses. Among the 295 patients, 180 had a poor-prog-
nosis signature and 115 had a good prognosis signature,
and the overall 10-year survival rates were 55% and 95%,
respectively. At 10 years, the probability of remaining free
of distant metastases was 51% in the group with a poor-
prognosis signature and 85% in the group with a good-
prognosis signature. The estimated hazard ratio (or rela-
tive risk of an endpoint at any given time) for distantProteome Science 2006, 4:5 http://www.proteomesci.com/content/4/1/5
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metastases in the group with a poor-prognostic signature,
as compared with that for the group with the good-prog-
nostic signature, was 5.1 (or 5.1 times greater). This ratio
remained significant even when the groups were analyzed
according to LN status. Multivariate Cox regression analy-
sis showed that the prognosis profile was a strong inde-
pendent factor in predicting disease outcome. The
resulting gene-expression profile was a more powerful
predictor of the outcome of disease in young patients with
breast cancer than the 2001 St. Gallen criteria, or the NIH
consensus criteria [13] based on clinical and histologic
characteristics. In fact, use of these criteria resulted in a
misclassification of a significant number of patients who
would be either under-treated or over-treated with adju-
vant therapy. Strikingly, their prognostic profile was inde-
pendent of LN involvement but rather, was based upon its
strong predictive power with respect to metastasis to non-
lymphatic tissues.
Shortly thereafter, Piccart and colleagues [14] presented
the validation of the Amsterdam 70-gene prognostic sig-
nature in LN-negative untreated breast cancer at the San
Antonio Breast Cancer Symposium. This validation was
performed as part of preparation for the launch of the
large prospective randomized clinical trial, MINDACT, for
LN-negative breast cancer, powered to look at the utility in
clinical practice of the Amsterdam 70-gene prognostic sig-
nature. Significant heterogeneity between the Amsterdam
and the external validation samples was found and is cur-
rently being investigated; however, the 70-gene prognos-
tic signature outperformed both the Nottingham
Prognostic Index and the St. Gallen criteria in predicting
time to distant metastases and OS. In addition, women of
the present series classified as low risk by the gene signa-
ture had a projected 5 year distant metastasis-free survival
of 95%. While the overall performance of the 70-gene
prognostic signature was inferior in this external valida-
tion series compared to the original Amsterdam series, the
results provide evidence for the clinical value of this new
genomic tool and are encouraging to mobilize forces for
the conduct of MINDACT.
A number of recent microarray studies have been pub-
lished which also deal with patient risk assessment in
those with LN-negative breast cancer. In one such study,
Wang and Co-Workers [15] analyzed primary tumour
samples from 286 LN-negative patients of all age-groups
and tumour sizes who had not received any adjuvant sys-
temic treatment. They identified a 76-gene signature that
showed 93% sensitivity and 48% specificity when tested
in an independent set of 171 LN-negative patients. This
set of genes was useful in identifying patients who devel-
oped distant metastasis within 5 years. By using this gene
signature only 52% of low-risk patients would be recom-
mended to receive systemic adjuvant chemotherapy com-
pared with 90% by the St. Gallen criteria. However, the
utility of this gene signature will have to be confirmed in
a larger cohort of patients prior to being used to recom-
mend that low-risk patients not be treated with unneces-
sary adjuvant systemic therapy. In another recent study, a
64-gene signature set was derived at by hierarchical clus-
tering of microarray data from 159 tumour samples from
both adjuvant-treated and untreated patients that identi-
fied genes associated with prognosis and impact of adju-
vant therapies, defined as distant metastasis or death
within 5 years [16]. This set of genes was then validated in
an independent cohort of 289 patients and could be used
to stratify patients into low, medium and high risk groups
that outperformed current clinical criteria. Patients in the
low risk group could potentially be spared adjuvant chem-
otherapy while those in the high risk group might benefit
from aggressive therapies such as anthracyclines or tax-
anes, however, this would have to be validated in a larger
prospective study.
Use of microarray data to predict response to 
therapy
Other recent microarray studies have focused on deter-
mining gene signatures of potential response of patients
to specific chemotherapy and hormonal therapy regi-
mens. In one such study, Chang and co-workers [7] have
shown that gene profiling can be used to accurately pre-
dict response to neoadjuvant docetaxel. The study
enrolled 24 subjects from whom core needle breast
tumour biopsies were taken. RNA was extracted from
these biopsies and subjected to microarray analysis that
resulted in the construction of a 92-gene predictor of
response set. In a cross-validation analysis, the classifier
correctly identified 10 of 11 responders and 11 of 13 non-
responders for an overall accuracy of 88%. Correlation
between RNA expression measured by the Affymetrix
arrays and semi-quantitative RT-PCR was also ascertained.
In addition, this classifier was validated in an independ-
ent set of 6 subsequent patients.
Similar results were achieved in a more recent study in
which an 85-gene signature was selected from over 2,400
genes using a high-throughput RT-PCR technique [17].
Samples from 44 breast tumour tissues, taken prior to
treatment, were analyzed and genes were selected based
upon differential expression between responders and
non-responders. They then devised a diagnostic system
based upon a weighted algorithm and used it to predict
the clinical response to docetaxel therapy in 26 patients
with over 80% accuracy.
A second neoadjuvant study was recently published using
cDNA arrays to develop a predictor of response to sequen-
tial paclitaxel and fluorouracil + doxorubicin + cyclophos-
phamide, involving 42 samples, 24 of which were used forProteome Science 2006, 4:5 http://www.proteomesci.com/content/4/1/5
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predictive marker discovery and 18 of which were used as
an independent validation set. A classifier with 74 mark-
ers was developed, with 78% accuracy, suggesting that
transcriptional profiling has the potential to identify a
gene expression pattern in breast cancer that may lead to
clinically useful predictors of chemotherapy response
[18]. A prospective clinical trial is currently underway to
validate these initial findings. And finally, in a study pub-
lished by Jansen and co-workers [19], a 44-gene signature
was used to predict tamoxifen-responsive and tamoxifen-
resistant tumours. They were able to predict tamoxifen-
resistance with an accuracy of 77% compared with 50–
60% accuracy based on ER status alone.
Additional work in ascertaining expression patterns for
other commonly prescribed chemotherapy regimens, like
anthracyclines and anti-metabolites, or targeted therapy,
like trastuzumab, is underway in the hope that these pat-
How the DASL Assay works Figure 1
How the DASL Assay works. A. The DASL Assay monitors gene expression with probe groups to query total RNA-generated 
cDNA target sequences. Total RNA, prepared from FFPE tumour tissue, is converted to cDNA using both biotinylated (desig-
nated as b) random nonamers and oligo dT. Primer sites, incorporated within each probe group, are used for PCR amplifica-
tion. Also within the probe group is an address sequence complementary to one of the 1536 sequences on the Sentrix® Array 
Matrix. Three probe group per gene are used that allows for detection of small (1.3) fold-changes in expression between sam-
ples. Probe groups are annealed to the biotinylated cDNA, followed by selection of the duplexes on streptavidin beads to 
remove unhybridized oligos. Correctly annealed, assay specific oligos are extended and ligated to a locus-specific oligo. The 
locus-specific oligo incorporates an address sequence and primer site for the generation of amplifiable products. B. Address-
containing templates, that are labeled with either cy3 or cy5 fluorescent dyes during PCR amplification, are subsequently 
hybridized to complementary address sequences immobilized to beads on the arrays. The array is then scanned to acquire 
intensity data.
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terns can be incorporated into predictive tests for the
selection of an appropriate treatment to minimize toxicity
and maximize efficacy for women with breast cancer. This
technology, hence, offers the means of identifying poten-
tially useful predictive clinical genes/gene signatures that,
when validated, may reduce unnecessary chemotherapy
treatment for women with breast cancer. In addition,
these results compare very favorably with the best existing
predictive factors for response to specific therapy, and
strongly suggest that after appropriately extensive valida-
tion, these identified genes/gene signatures will be useful
for treatment selection. One major caveat, though, is that
the inability to routinely use FFPE tumour tissue samples
in microarray analysis restricts the use of this technology
to relatively small sample sets and requires validation of
potential genes/biomarkers using additional genomic
(qRT-PCR, DASL) and/or proteomic (TMA) platforms
(dealt with in subsequent sections below).
Use of FFPE tumour tissue for downstream 
analysis platforms
While the above mentioned microarray studies have
relied upon freshly-frozen tissue samples, this material is
difficult to collect for large scale studies, cumbersome to
process and expensive to store long-term. In the past few
years, enormous progress has been made in developing
technologies to exploit FFPE tumour tissue samples for
gene expression and proteomic analysis. FFPE tissue is the
standard processing methodology practiced in pathology
laboratories the world-over. These samples are highly sta-
ble at room temperature, are easily stored and, most
importantly, make up a vast archive of pathologically well
characterized and well annotated clinical samples from
randomized trials that exist worldwide. FFPE tumour tis-
sue samples are, therefore, an immense resource that are
amenable for conducting both retrospective and prospec-
tive biomarker investigations which will allow for well-
controlled hypothesis testing.
Several groups have illustrated that it is feasible to extract
and purify RNA from such FFPE tissue and to perform
gene expression profiling despite the chemical modifica-
tion and often fragmentation of RNA that occurs due to
the fixation process [[20-27]]. With the development of
qRT-PCR technology, it is now possible to detect rare mes-
sages in FFPE tissue and to examine the variation of
expression over quite a large dynamic range. Amplicons
are designed specifically on small segments of DNA (less
than 100 bps) to achieve close to 100% efficiency for all
amplicons regardless of their length and nucleic acid com-
position. This is also ideal for fixed tissue since most RNA
species in FFPE tissue are degraded to fragments that are ≥
100 bp; as such, transcripts can be easily detected by oli-
gonucleotide primers that span small amplicons of less
than 100 bp. The potential of this technology, as pointed
out above, becomes even more attractive in that it permits
the analysis of thousands of well annotated archived tis-
sue samples without the need to collect the relatively com-
plicated freshly-frozen tissue. Platforms that can use this
wealth of available samples should, therefore, shorten the
time for biomarker development and validation and is
currently being exploited in the Oncotype DX assay [28]
(see below).
FFPE tumour tissue samples are routinely used for immu-
nohistochemical analysis and with the development of
TMA technology, large tissue sample sets can be used to
evaluate the role of potential biomarkers as diagnostic or
predictive tools in breast cancer (see below).
Tissue Micro-Arrays for the evaluation of breast 
tumour biomarkers
In the TMA format, an array comprises hundreds of differ-
ent patient samples using cores as small as 0.6 mm taken
from FFPE tumour blocks [29]. Each array is incubated
with one detection protein (i.e., antibody): a single ana-
lyte endpoint is measured and directly compared across
multiple samples (Fig. 1). Probing multiple arrays with
different specific antibodies provides the effect of generat-
ing a multiplex read-out. TMAs, thus, were developed as a
means of identifying protein targets in as many as 1,000
cylindrical FFPE tissue specimens taken from individual
tumours. This has opened the door to the analysis of pro-
tein expression using archival tissue, and TMAs provide a
cost-effective method for examining multiple biomarkers
on a large series of retrospective and prospective breast
cancer cases. The TMA platform has been employed to
explore a limited number of biomarkers that are poten-
tially involved in malignant progression and tumour biol-
ogy using similar analytical methods used to analyze
microarray data.
The first application of this high-throughput technique
was towards the identification of six genes amplified in
breast cancer as well as p53 and ER in order to define
novel subgroups [30]. However, in order for TMAs to gain
broad acceptance, Camp and co-workers [31] showed that
TMAs were basically immunohistochemically equivalent
to whole tissue sections. They proved this by studying the
expression of three common antigens in invasive breast
carcinomas; ER, PGR and HER2. They found that analyz-
ing two 0.6 mm cores from each tumour sample was com-
parable to the analysis of a whole tissue section in greater
than 95% of cases. As importantly, they were able to per-
form TMAs on archival tissue dating back more than 60
years. Therefore, although tissue cores used in TMA stud-
ies are small compared with full sections, their effective-
ness as tools in cancer studies has been rigorously
validated over a short period of time by a number of
investigators [[32-35]]. Since these initial publications onProteome Science 2006, 4:5 http://www.proteomesci.com/content/4/1/5
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the development and use of TMAs in the analysis of
tumours from breast cancer patients, this technique has
been widely applied to the study of breast cancer both
with regard to classification and tumour markers.
Callagy and colleagues [35] sought to validate microarray-
derived classification schemes using FFPE tissue from
well-annotated archival samples. A TMA study was under-
taken to sub-classify 107 breast cancers using thirteen dif-
ferent putative protein biomarkers. Analysis, using an
unsupervised clustering algorithm, subdivided the
tumours into two main groups that correlated with
tumour grade and nodal status. Not surprisingly, no sin-
gle biomarker tested could identify these groups; classifi-
cation, thus, requires the input of several proteins in order
to subdivide tumours into clinically relevant subgroups.
Based upon their 13 biomarkers, tumours could be subdi-
vided into 2 main groups, ER-positive and ER-negative.
ER-positive tumours fell into 2 subdivisions; subsets A
and B both expressing luminal cytokeratins 8/18 but
showing differential expression of HER2, c-Myc and PGR.
Subset A was most reminiscent of luminal subtype A
described using expression microarray analysis [6]. ER-
negative tumours could be subdivided into subsets C and
D, but only subset D expressed basal cytokeratins, suggest-
ing that basal-type tumours form a distinct subset of ER-
negative breast cancer. This data, therefore, supported the
findings from previous microarray studies conducted on a
limited number of samples [6,9]. However, this pilot
study did not show any correlation between the tumour
classification and survival, underscoring the need for
determining the optimal set of biomarkers required to
generate a robust classification system for breast cancer.
In two more recent TMA studies, described below, hierar-
chical clustering analysis did show prognostic signifi-
cance. Makretsov and co-workers [36] evaluated 31
biomarkers in 438 invasive breast carcinoma cases with
15.4 years of follow-up. Of these 31 biomarkers, 17 were
prognostically significant while an additional 4 showed a
trend but did not reach significance. They then used these
21 immunomarkers to conduct unsupervised hierarchical
cluster analysis and were able to segregate the samples
into three prognostically significant cluster groups. This
clustering could also be achieved with only 11 biomarkers
(ER, PGR, HER2, p53, Ki67, CA IX, TIP1, stromal CD117,
PTEN, p63 and CK5/6) which contributed significantly to
their cluster group designation. Cluster group 1 was ER-
positive and PGR-positive, while cluster groups 2 and 3
were, for the most part, negative for these steroid hor-
mone receptors. With regard to survival, only cluster
groups and LN status were significant as independent
prognostic variables. Indeed, some tumours that
expressed high levels of ER were classified as belonging to
group 2 or 3, ER-negative groups. Thus, expression of
biomarkers associated with tumour aggressiveness can
override positive prognostic factors such as ER. It is espe-
cially important to be able to determine the nature of LN-
negative breast cancer so that toxic chemotherapy is only
administered to those patients that need it while sparing
others that don't.
A larger TMA study was recently completed in which
1,076 invasive breast cancer cases were evaluated using 25
biomarkers [37]. Biomarkers used in the study were
selected based upon; 1) their well established role that
they play in breast carcinogenesis; 2) their ability to act as
discriminator genes that can stratify breast cancer in to
distinct groups, identified in microarray studies; and 3)
their ability to identify specific forms of differentiation.
Markers came from the following groups: luminal, basal,
hormone receptors, EGFR family members, tumour sup-
pressor genes, cell adhesion molecules, mucins, apocrine
differentiation and neuroendocrine differentiation. Six
main clusters were identified by hierarchical cluster anal-
ysis: Groups 1 and 2 were ER-positive, luminal, while
groups 3 & 6 were HER2-positive, luminal. However,
group 3 was distinguishable from group 6 based upon
strong MUC1 and weak E-cadherin expression in group 3
and weak MUC1 and strong E-cadherin expression in
group 6. Group 4 only contained 4 tumours which were
all EGFR-positive but ER-negative. Finally, group 5 was
basal, HER2-negative and ER-negative. This study clearly
showed that apparent homogeneous tumours could be
classified into biologically and clinically distinct groups
and it confirmed the previous classification of breast can-
cer carried out by microarray analysis [6].
BRCA1 and BRCA2 tumours have also recently been sub-
jected to TMA analysis in which 37 biomarkers were used
to define hormone receptor, cell cycle, apoptosis and
basal cell status [38]. The TMA contained cores from 20
BRCA1, 14 BRCA2 and 59 sporadic age-matched breast
carcinomas. In agreement with previous work, BRCA1
showed phenotypic characteristics that were notably dif-
ferent from BRCA2. Analysis of all sporadic and hereditary
cases by unsupervised hierarchical clustering revealed two
main branches, an ER-positive and an ER-negative cluster.
Within the second cluster, BRCA2 carcinomas were inter-
mixed with sporadic tumours, however, most BRCA1 car-
cinomas, found in the first cluster, were grouped into a
main sub-branch that included tumours that expressed
basal cell markers and/or p53. There was a clear separa-
tion of this sub-group from HER2-positive sporadic carci-
nomas. In fact, by FISH analysis, HER2 was not amplified
in any of the BRCA tumours but was amplified in 22% of
the sporadic ones. In contrast to this, c-Myc was found to
be amplified in 23% (3/13) of BRCA1 and 67% (4/6)
BRCA2 tumours. With regard to individual markers, the
most striking difference between BRCA1 and BRCA2Proteome Science 2006, 4:5 http://www.proteomesci.com/content/4/1/5
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hereditary breast carcinomas was in expression of cell
cycle proteins. BRCA2 tumours expressed cyclin D1 and
D3, cyclin D kinase (CDK) 4 and the CDK inhibitors, p16,
p21, and p27, which were all downregulated in BRCA1.
BRCA1 could be characterized as having a basal pheno-
type, ER-negative and HER2-negative, with up-regulation
of cyclin A and caspase 3, but downregulation of cyclin
D1 and D3, CDKIs (p16, p21, p27), and BCL2, the oppo-
site phenotype from most BRCA2 carcinomas.
TMAs have also been used to evaluate breast carcinomas
with a limited number of biomarkers in order to test the
hypothesis that a particular marker has biological and/or
therapeutic significance in breast cancer. It has been
known for some time now that the long term use of non-
steroidal anti-inflammatory drugs (NSAIDs) are linked to
a 40–50% reduction in colon cancer [39]. The effect of
NSAIDs on colon cancer is caused by inhibition of
cyclooxygenase-2 (Cox-2) resulting in the blockade of
synthesis of prostaglandins (PG), foremost PGE2, that
promotes tumourigenesis, invasion and metastasis by
stimulating angiogenesis and inhibiting immune surveil-
lance [40]. However, the importance of Cox-2 in breast
cancer has not been established. TMA analysis was per-
formed on 200 breast carcinomas and Cox-2 was detected
in 41% of cases [41]. Cox-2 expression was positively cor-
related with HER2 and Ki-67, a marker of proliferation,
but was inversely correlated with expression of ER and
PGR. A potential role of Cox-2 in breast cancer is based
upon its role in proliferation [42], apoptosis [43] as well
as angiogenesis [44]. Although a significant association of
Cox-2 with disease-free survival (DFS) (or the survival
period spanning the time from surgery to recurrence of
cancer) was not achieved, Cox-2 still represents an inter-
esting target in breast cancer [45].
Deacetylation of histones by histone deacetylases
(HDACs) counteracts histone acetylation resulting in
DNA that is inaccessible causing suppression of gene tran-
scription. Over the past few years, inhibitors of HDACs
have shown promise as potential anti-cancer agents [46],
and have been found to inhibit cell growth and induce
apoptosis in breast cancer cells [[47-50]]. A TMA study
[51], using tumour samples from 200 breast cancer
patients, was conducted that focused on HDAC-1 and
HDAC-3, from HDAC class I, since these play a role in
proliferation and cell survival of mammary tumour cells
and can interact either directly or indirectly with the ster-
oid hormone receptors ER and PGR as well as the tumour
suppressor p53 [[52-54]]. They found that HDAC-1 was
significantly associated with improved DFS but not with
the classical prognostic factors. In a sub-group of ER/PGR-
positive, HER2-negative tumours, expression of HDAC-1
was associated with a better DFS probability then HDAC-
1 negative tumours. In general, HDAC-1 expression was
linked to less aggressive tumours while those tumours in
which HDAC-1 was not detected were more aggressive.
Thus, HDAC-1 expression could be added to the list of
potential markers of prolonged DFS and tumour aggres-
siveness.
Abnormal expression of a number of mucins, large glyco-
proteins expressed by many epithelial cells, has been
implicated in many different cancers. Overexpression of
MUC1 along with MUC2 and MUC3 has been detected in
breast cancer [55]. The precise role that mucins play in
cancer in general and breast cancer in particular has yet to
be determined. In a study by Rakha and colleagues [56],
expression of a number of mucins (MUC1, MUC2,
MUC3, MUC4, MUC5AC and MUC6) were profiled by
TMA in 1447 cases of invasive breast cancer in order to
evaluate their prognostic significance. MUC1 and MUC3
were detected in the majority of breast cancer cases. Most
strikingly, it was the subcellular localization of these two
mucins and not their expression level that was of prognos-
tic value; membranous staining being associated with
poor OS compared with apical staining and a more
favourable OS. The other mucins did not appear to have
any prognostic value in predicting outcome.
One of the main objectives for the use of TMA technology
is to identify prognostically relevant groups of breast can-
cer patients and, in conjunction with data from other
molecular profiling studies, come up with an optimal
panel of biomarkers that can be validated in independent
sample sets. In the end, the aim of many of these studies
is to be able to identify those biomarkers that can be used
in a clinical setting to rapidly characterize a patient's
tumour type and use that information to apply the most
appropriate treatment strategy. Therefore, molecular clas-
sification of breast tumours will contribute important
information to the traditional histopathologic classifica-
tion currently in use. However, the use of TMAs requires a
prior knowledge of the potential biomarkers being
assessed and, therefore, can not readily contribute to the
discovery of novel biomarkers.
qRT-PCR: The Oncotype DX prognostic assay 
for tamoxifen-treated patients
QRT-PCR technology represents an important genomic
platform that has great sensitivity and specificity, covers a
wide dynamic range, and requires minute amounts of
cells or tissue from which to isolate RNA. While qRT-PCR
has significant diagnostic potential, it has to date been
limited to viral diagnostics. Genomic Health Inc. (GHI) in
collaboration with National Surgical Adjuvant Breast and
Bowel Project (NSABP) researchers have recently devel-
oped and commercialized a predictive gene signature-
based assay for ER-positive, LN-negative tamoxifen-
treated breast cancer tumours, named Oncotype DX [28],Proteome Science 2006, 4:5 http://www.proteomesci.com/content/4/1/5
Page 9 of 15
(page number not for citation purposes)
measuring the expression of 21 genes on archival FFPE
pathology blocks. GHI/NSABP researchers studied 447
patients from 3 independent clinical studies to test the
relationship between expression of 250 candidate cancer-
related genes (selected from published sources and public
databases) and recurrence. They subsequently derived
their gene list (16 genes plus 5 reference genes) and recur-
rence score (RS) algorithm which was prospectively tested
on 668 patients enrolled in the NSABP trial B-14 and was
found to provide accuracy and precision in predicting the
likelihood of distant recurrence. Moreover, the RS per-
formance exceeded standard measures such as age,
tumour size, and tumour grade, both in prognostic power
and in reproducibility [28]; this technology has been
recently approved by the US Food and Drug Administra-
tion for clinical application.
Since then, this technique has undergone extensive testing
regarding validation and prognostic capabilities: 1) the
previously described RS has been shown to predict
response to chemotherapy [57]. This work demonstrated
that a higher RS is associated with a higher likelihood of
pathologic complete response in patients treated with
doxorubicin/paclitaxel neoadjuvant therapy in locally
advanced breast cancer; 2) RS was shown to be not only
prognostic for tamoxifen-treated patients, but also
strongly predictive of response and benefit from
tamoxifen in NSABP B-14 [28]; 3) moreover, RS predicted
the magnitude of chemotherapy benefits in NSABP B-20:
patients with tumours that had a low RS, derived minimal
if any benefit from chemotherapy. Patients with tumours
that had a high RS, derived a large absolute benefit from
chemotherapy; 4) the initial B-14 prognostic data has
been subsequently confirmed in a validation study of 220
evaluable cases and 570 matched controls in the Northern
California Kaiser Permanente [58]. RS was strongly prog-
nostic of breast cancer specific mortality in this popula-
tion similar to the B-14 population. Finally, 5) the RS
results from NSABP B-14 were correlated and compared
with 10-year outcome data estimated using AO [59]. RS
and AO predicted outcomes correlated relatively weakly
(concordance = 48%) with RS appearing to correlate more
strongly with outcome than AO. Hence, each algorithm/
assay clearly contains independent prognostic informa-
tion; it would, therefore, be reasonable to combine these
information sets in future prognostic and predictive algo-
rithms.
Clearly, the ability to validate a set of biomarkers on large
FFPE sample sets is what allowed this assay to go forward
and move into the clinic. Newer technology, such as the
one discussed below, would allow for the analysis of large
sets of potential biomarkers using RNA prepared from
FFPE tumour tissue.
The DASL assay
The DASL assay from Illumina Inc. has been specifically
designed as a gene expression profiling system to generate
reproducible data from degraded RNAs such as those
derived from FFPE tumour samples. The assay is a cross
between microarray and qRT-PCR technologies and
endeavors to combine them into one platform that can be
formatted to analyze expression of a panel of selected
genes in a single clinical sample using a minimal amount
of total RNA (≤ 200 ng total RNA per assay).
Potential advantages of DASL over other competing
expression technologies include; 1) use of FFPE tissue
samples as old as 24 years (unpublished data, Illumina);
2) high throughput, up to 96 clinical samples on one
array plate; and 3) the use of a custom gene panel, at least
512 genes per array.
Each array contains 50,000 beads with 1,534 different
addresses and 3 unique addresses per gene. Each bead has
hundreds of thousands of capture probes (23-mers) on
fibers with one unique address. Therefore, analysis of
~500 genes per array panel can be conducted at ~30-fold
redundancy (Fig. 2). Oligonucleotides are designed such
that there are three non-overlapping probe pairs per gene.
This results in a 1,506-plex measurement for each sample.
It has been shown that using this number of probes per
gene lends the assay the necessary sensitivity and repro-
ducibility for quantitative detection of differential expres-
sion using RNA from FFPE tissues [8,60]. In the
How TMAs are constructed Figure 2
How TMAs are constructed. Cores (0.6–2.0 mm in diame-
ter) are taken from FFPE tumour tissue donor blocks and 
arrayed into a recipient block. The recipient block is then 
sectioned (5 µm) onto a glass slide and processed by immu-
nohistochemistry for biomarkers. The analysis can be manual 
or automated and the data is linked to clinical information.
Finished Recipient
TMA block
Block is sectioned to create the TMA
Donor Punch
FFPE tissue sample
in donor blockProteome Science 2006, 4:5 http://www.proteomesci.com/content/4/1/5
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procedure, random priming is used for cDNA synthesis
and, therefore, probes are designed such that they can tar-
get any unique region of the gene without limiting the
selection of the optimal probe to the 3' ends of transcripts.
In addition, due to the small size of the targeted gene
sequence (50 nucleotides), along with the use of random
primers in the cDNA synthesis, this allows for detection of
RNAs that are otherwise too degraded for conventional
microarray analysis.
The 5' oligonucleotides consist of two parts: the gene spe-
cific sequence and a universal PCR primer sequence. The
3'-oligos consist of three parts: the gene specific sequence,
a unique address sequence which is complementary to
one of 1,506 capture sequences on the array and a univer-
sal PCR primer sequence at the 3' end. A single address
sequence is uniquely associated with a single target site.
This address sequence allows the PCR-amplified products
to hybridize to a universal microarray bearing the comple-
mentary address sequences.
In the report by Bibikova et al (2004), they showed that
the DASL assay could be applied to breast and colon can-
cer FFPE tumor samples. Using a 231 gene cancer panel
and cluster analysis, they were able to separate breast from
colon tissue types and subsequently, divide each tissue
sample set into cancer versus normal. The goal, therefore,
is to use FFPE tumour tissue samples in conjunction with
the DASL platform to potentially identify differential sig-
nature gene sets that can be used for diagnosis, prognosis
and/or monitoring of disease. This technology is just
beginning to be applied to cancer research and as its use
becomes more widespread it has the potential to have an
important impact on translational breast cancer research.
Proteomic analysis of serum in breast cancer
The ability to detect cancer early before it has metastasized
throughout the body is one of the keys to ensuring that
treatment has the highest likelihood of effectuating a
complete cure. Of equal importance is the potential to
monitor a patient's response to therapy or the potential of
recurrence in real-time. What is required, therefore, is a
reliable non-invasive diagnostic test. Serum has the
advantage of being a readily accessible body fluid that is
protein-rich and that is well-suited to proteomic analysis
and hence, biomarker discovery or monitoring of a
patient's condition with time. As an approach to serum
biomarker discovery, proteomic pattern analysis has been
developed as a means to identify novel markers when
comparing samples from patients with disease with those
from healthy subjects without any prior knowledge or
bias of what the proteins are [61]. Interesting peaks can
then be subsequently identified and confirmed as poten-
tial biomarkers. Differences in proteomic patterns in
serum of diseased compared to normal can be due to; 1)
overexpression; 2) abnormally shed proteins or protein
fragments; 3) modified proteins; 4) proteolytically
cleaved proteins; or 5) degradation due to the proteosome
pathway. Only a small amount of serum, 1–20 µL, is
required for analysis. Samples are added to protein-chip
arrays, available in a number of different chromato-
graphic surfaces, which are used to capture proteins based
on charge or hydrophobicity. The retained proteins are
then subjected to surface-enhanced laser-desorption ioni-
zation time-of-flight mass spectrometry (SELDI-TOF/MS),
a proteomic platform amenable to high throughput anal-
ysis of serum samples (Fig. 3) (for a review of the technol-
ogy see [62]).
An early study to find biomarkers in serum of breast can-
cer patients using SELDI-TOF/MS and Ciphergen Protein-
ChipR arrays was undertaken by Li and colleagues [63].
They studied serum samples from 103 breast cancer
patients at different clinical stages (stage 0 to III); 41
healthy women and 25 women with benign breast dis-
eases. They identified three biomarkers that could dis-
criminate breast cancer patients from the noncancer
patients with high sensitivity (93%) and high specificity
(91%). These three biomarkers were selected using stage
0-I cancer versus noncancer controls as the training set
and later-stage cancer as the test set in order to try and
identify early-stage breast cancer biomarkers. The biomar-
kers, however, were not sensitive to the stages of cancer
patients. Therefore, these markers appear to reflect the
malignant nature of the tumour rather than its progres-
sion. Similar results were obtained in a study of serum
proteins from 49 breast cancer patients, 51 patients with
benign breast diseases and 33 healthy women [64]. Using
a combination of proteomics and bioinformatics, four
candidate biomarkers of breast cancer were found and
were used in the development of diagnostic models. The
four putative markers could be used to distinguish
between breast cancer patients and women who were
healthy or had benign breast diseases.
SELDI-TOF/MS analysis of serum proteins can also be
potentially applied to identify patients who would benefit
from various breast cancer therapies as well as those who
would experience adverse effects caused by chemothera-
pies used in breast cancer. In one such study, proteins
with molecular weights of 7790 and 9285 Da were
detected in 5 patients treated with docetaxel but were not
detected in one patient who experienced severe, acute
adverse effects [65]. Pusztai and colleagues [66] applied
SELDI-TOF/MS to investigate proteomic changes in
plasma from 69 Stage I-III breast carcinoma patients
treated with paclitaxel or 5-fluorouracil, doxorubicin, and
cyclophosphamide (FAC) chemotherapy and 15 healthy
subjects. They detected a single chemotherapy-induced
peak that did not, however, correlate with the tumourProteome Science 2006, 4:5 http://www.proteomesci.com/content/4/1/5
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response, as well as five additional peaks that could distin-
guish breast carcinoma patients from normal healthy
women.
As with many of these initial studies, further standardiza-
tion and independent validation using larger numbers of
specimens is required to ensure the performance of these
selected biomarkers [67]. While a great deal more has to
be done to validate potential biomarkers discovered in the
serum from breast cancer patients, the potential is there to
combine these biomarker analyses with other diagnostic
procedures for the early detection and monitoring of
response to therapy of breast cancer patients.
A systems biology approach to data integration
Cancer in general, and breast cancer in particular, is a
highly complex and heterogeneous disease which
involves a succession of genetic changes that eventually
results in the conversion of normal cells into cancerous
ones. Hanahan and Weinberg have proposed that human
tumours are governed by a common set of six acquired
capabilities; 1) self-sufficiency in growth signals; 2) insen-
sitivity to anti-growth signals; 3) evasion of apoptosis; 4)
limitless replicative potential; 5) sustained angiogenesis;
and 6) tissue invasion and metastasis [68]. A complete
knowledge of these processes will require the integration
and analysis of massive amounts of data, as is being col-
lected from current genomic and proteomic platforms, as
well as newer technologies [69].
Although systems biology is an emerging field, progress is
being made and a number of computational approaches
have been applied to the biological complexity of cancer.
Christopher and colleagues [70] have developed a com-
puter simulation of a human cancer cell. These whole cell
mathematical models integrate vast amounts of data that
include many interacting genes, proteins and protein
modifications. They created a model of networks, both
signal transduction and gene expression, that are involved
in the control of cell proliferation and apoptosis and
showed that it could be used to test the efficacy of drugs as
well as explore various therapeutic targets. Computational
methods are also being applied to expression data, both
genomic and proteomic, in order to develop graphical
models of gene-protein regulatory networks [71]. A
number of additional computational approaches are
being used in order to incorporate and connect experi-
mental data so that biological systems can be simulated
and used for hypothesis testing [72].
As systems biology matures, data that has been collected
from various "omic" platforms will be available for input
into novel computational systems biology models that
will help unravel the complexity of cancer. Applying this
systems biology approach to breast cancer has the poten-
tial to more rapidly lead to early diagnosis and the indi-
vidualization of treatment.
Conclusion
Microarray analysis of breast tumour tissue samples has
heralded in a new age of molecular classification of
tumours that has resulted in the identification of specific
subtypes yielding new insights into prediction of disease
outcome and response to therapy. However, this genomic
platform is currently limited, for the most part, to analyz-
ing frozen tumour tissue specimens, which are not readily
available, thus, preventing large scale validation studies to
be conducted using this technology. FFPE tumour tissue
samples are, therefore, the most important and abundant
source of material available from randomized clinical tri-
als that will allow for well-controlled hypothesis testing to
be conducted.
Thus, technologies designed for use with FFPE samples are
critical in order to test and validate predictive gene signa-
tures and biomarkers derived from microarray studies.
The ability to tap into this resource is starting to have an
impact as seen in the application of the qRT-PCR-based
Oncotype DX assay to breast cancer patients. TMAs are
Analysis of serum proteins using ProteinChip arrays and  SELDI-TOF/MS Figure 3
Analysis of serum proteins using ProteinChip arrays and 
SELDI-TOF/MS. A. Crude serum sample is placed (and proc-
essed) on a ProteinChip array which contains chemically 
(cationic, anionic, hydrophobic, hydrophilic, etc.) or biologi-
cally treated surfaces for specific interaction with proteins of 
interest. Proteins, thus, bind to chemical or biological "dock-
ing sites" on the ProteinChip surface. Non-binding proteins, 
salts, and other contaminants are washed away, eliminating 
sample "noise". B. Retained proteins are "eluted" from the 
ProteinChip array by Surface-Enhanced Laser Desorption/
Ionization (SELDI). Ionized proteins are detected and their 
mass accurately determined by Time-of-Flight Mass Spec-
trometry (TOF/MS).
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also being used in the analysis and validation of biomar-
kers discovered through microarrays. Newer technology,
such as the DASL assay, which has recently become avail-
able, holds the promise of further expanding the utiliza-
tion of these precious tissue resources for both testing and
validation of potential biomarkers. In addition, protein-
chip technology in conjunction with SELDI-TOF/MS has
opened up the entire field of protein pattern analysis of
biological fluids in general and serum in particular. This
proteomic platform has shown promise in both the dis-
covery of biomarkers for early diagnosis and monitoring
of disease progression.
The road to individualization of treatment for breast can-
cer patients is not an easy one with many twists and turns
that will require an understanding of copious amounts of
data generated from both genomic and proteomic plat-
forms. The integration of all of this data using a systems
biology approach will also be crucial in extracting the nec-
essary information that will eventually lead to a detailed
understanding of breast cancer.
We are leaving a past where the patient received the best
therapy based solely on historical clinical efficacy data
obtained from large populations of patients but without
any specific prediction of individual response. We are
entering an era where each and every patient will receive
individualized therapy based upon the key signaling path-
ways driving her tumour; we believe that a combined plat-
form approach incorporating both genomics and
proteomics in a systematic way is critical for moving
towards this goal.
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